The present study evaluated the pharmacokinetics of methotrexate (MTX, CAS 59-05-2) and 7-hydroxymethotrexate (7-OHMTX, CAS 5939-37-7) in children with acute lymphoblastic leukemia (ALL) with particular interest devoted to the renal excretion at the steady-state and to the relationships between total (CL) and renal clearances (CL(R)) of both compounds. Ten children (seven girls) aged 8.5 years (2.9-16) years with standard or medium-risk ALL received four 24-h i.v. infusions of high-dose MTX (HDMTX, 5 g/m2) with leucovorin (CAS 58-05-9) rescue according to the ALL-BFM-95 protocol. MTX and 7-OHMTX were assayed in plasma and urine by high-performance liquid chromatography. At the steady-state, the clearance (CL) of MTX (6.28 +/- 2.79 l h(-1)) was correlated with its CL(R) (r(s) = 0.79, p < 0.0001) which accounted for 61% (SD 26%) of the former. There were weak correlations between pretreatment values of creatinine clearance calculated using Schwartz's formula and the drug's CL (r(s) = 0.30, p < 0.05) or CLR (r(s) = 0.41, p < 0.02). In contrast, the CL(R) accounted for only 26% (SD 15%) of the metabolite's CL which was estimated assuming 10% conversion of MTX to 7-OHMTX. The CL values of both compounds were highly correlated (r(s) = 0.86, p < 0.0001). The CL(R) of the parent compound was on the average 9-fold higher (range: 3.5- to 17-fold) and was strongly correlated with the CL(R) of the metabolite (r(s) = 0.87, p < 0.0001). The ratio 7-OHMTX/MTX of urinary concentrations was between 2.4 and 9.8% with the mean value of 4.1%. This study suggests that during the 24-h i.v. infusions of HDMTX to children with ALL, the exposure of patients to 7-OHMTX can be reasonably well predicted from the knowledge of MTX concentrations. The steady-state renal CLs, total CLs as well as urinary concentrations of the parent compound and metabolite are highly correlated and the correlation of plasma concentrations is moderate. Therefore, it is unlikely that simultaneous evaluation of 7-OHMTX and MTX steady-state concentrations could improve the predictive performance of the latter towards the response or the risk of complications, although future larger studies should verify this conclusion.

Department of Paediatrics Charles University Prague Faculty of Medicine and Hospital Hradec Králové Czech Republic

Department of Pharmacology Charles University Prague Faculty of Medicine Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12026553

003      

CZ-PrNML

005      

20160224074012.0

007      

ta

008      

120816s2010 gw f 000 0#eng||

009      

AR

024    7_

$a 10.1055/s-0031-1296353 $2 doi

035    __

$a (PubMed)21265469

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Chládková, Jiřina, $d 1963- $7 xx0076213 $u Department of Paediatrics, Charles University in Prague, Faculty of Medicine and Hospital, Hradec Králové, Czech Republic

245    10

$a High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate / $c J. Chládková, J. Hak, J. Martínková, J. Chládek

520    9_

$a The present study evaluated the pharmacokinetics of methotrexate (MTX, CAS 59-05-2) and 7-hydroxymethotrexate (7-OHMTX, CAS 5939-37-7) in children with acute lymphoblastic leukemia (ALL) with particular interest devoted to the renal excretion at the steady-state and to the relationships between total (CL) and renal clearances (CL(R)) of both compounds. Ten children (seven girls) aged 8.5 years (2.9-16) years with standard or medium-risk ALL received four 24-h i.v. infusions of high-dose MTX (HDMTX, 5 g/m2) with leucovorin (CAS 58-05-9) rescue according to the ALL-BFM-95 protocol. MTX and 7-OHMTX were assayed in plasma and urine by high-performance liquid chromatography. At the steady-state, the clearance (CL) of MTX (6.28 +/- 2.79 l h(-1)) was correlated with its CL(R) (r(s) = 0.79, p < 0.0001) which accounted for 61% (SD 26%) of the former. There were weak correlations between pretreatment values of creatinine clearance calculated using Schwartz's formula and the drug's CL (r(s) = 0.30, p < 0.05) or CLR (r(s) = 0.41, p < 0.02). In contrast, the CL(R) accounted for only 26% (SD 15%) of the metabolite's CL which was estimated assuming 10% conversion of MTX to 7-OHMTX. The CL values of both compounds were highly correlated (r(s) = 0.86, p < 0.0001). The CL(R) of the parent compound was on the average 9-fold higher (range: 3.5- to 17-fold) and was strongly correlated with the CL(R) of the metabolite (r(s) = 0.87, p < 0.0001). The ratio 7-OHMTX/MTX of urinary concentrations was between 2.4 and 9.8% with the mean value of 4.1%. This study suggests that during the 24-h i.v. infusions of HDMTX to children with ALL, the exposure of patients to 7-OHMTX can be reasonably well predicted from the knowledge of MTX concentrations. The steady-state renal CLs, total CLs as well as urinary concentrations of the parent compound and metabolite are highly correlated and the correlation of plasma concentrations is moderate. Therefore, it is unlikely that simultaneous evaluation of 7-OHMTX and MTX steady-state concentrations could improve the predictive performance of the latter towards the response or the risk of complications, although future larger studies should verify this conclusion.

650    _2

$a mladiství $7 D000293

650    _2

$a analýza rozptylu $7 D000704

650    _2

$a antimetabolity antitumorózní $x krev $x farmakokinetika $x moč $7 D000964

650    _2

$a plocha pod křivkou $7 D019540

650    _2

$a dítě $7 D002648

650    _2

$a předškolní dítě $7 D002675

650    _2

$a vysokoúčinná kapalinová chromatografie $7 D002851

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a poločas $7 D006207

650    _2

$a lidé $7 D006801

650    _2

$a intravenózní infuze $7 D007262

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a methotrexát $x analogy a deriváty $x krev $x farmakokinetika $x moč $7 D008727

650    _2

$a lymfoblastická leukemie-lymfom z prekurzorových T-buněk $x metabolismus $7 D054218

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Hak, Jiří $7 xx0063273 $u Department of Paediatrics, Charles University in Prague, Faculty of Medicine and Hospital, Hradec Králové, Czech Republic

700    1_

$a Martínková, Jiřina, $d 1940- $7 nlk19990073537 $u Department of Pharmacology, Charles University in Prague, Faculty of Medicine, Hradec Králové, Czech Republic

700    1_

$a Chládek, Jaroslav, $d 1962- $7 xx0057856 $u Department of Pharmacology, Charles University in Prague, Faculty of Medicine, Hradec Králové, Czech Republic

773    0_

$w MED00000597 $t Arzneimittel-Forschung $x 0004-4172 $g Roč. 60, č. 12 (2010), s. 769-775

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21265469 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m $z 0

990    __

$a 20120816 $b ABA008

991    __

$a 20160224074022 $b ABA008

999    __

$a ok $b bmc $g 948595 $s 783899

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2010 $b 60 $c 12 $d 769-775 $i 0004-4172 $m Arzneimittel-Forschung $n Arzneimittelforschung $x MED00000597

LZP    __

$b NLK122 $a Pubmed-20120816/11/01